TG Therapeutics Completes Rolling Submission Of Biologics License Application To The FDA For Ublituximab In Combination With UKONIQ As A Treatment For Patients With Chronic Lymphocytic Leukemia
TG Therapeutics Completes Rolling Submission Of Biologics License Application To The FDA For Ublituximab In Combination With UKONIQ As A Treatment For Patients With Chronic Lymphocytic Leukemia
TG治療公司完成向FDA滾動提交Ublituximab與UKONIQ聯合治療慢性淋巴細胞白血病患者的生物製品許可證申請
TG Therapeutics Completes Rolling Submission Of Biologics License Application To The FDA For Ublituximab In Combination With UKONIQ As A Treatment For Patients With Chronic Lymphocytic Leukemia
TG治療公司完成向FDA滾動提交Ublituximab與UKONIQ聯合治療慢性淋巴細胞白血病患者的生物製品許可證申請
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。